Mineralys Therapeutics Statistics
Total Valuation
MLYS has a market cap or net worth of $655.36 million. The enterprise value is $316.80 million.
| Market Cap | 655.36M |
| Enterprise Value | 316.80M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MLYS has 49.65 million shares outstanding. The number of shares has increased by 81.31% in one year.
| Shares Outstanding | 49.65M |
| Shares Change (YoY) | +81.31% |
| Shares Change (QoQ) | +11.87% |
| Owned by Insiders (%) | 2.86% |
| Owned by Institutions (%) | 95.95% |
| Float | 23.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.00 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.06, with zero debt.
| Current Ratio | 18.06 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.50% and return on invested capital (ROIC) is -32.03%.
| Return on Equity (ROE) | -32.50% |
| Return on Assets (ROA) | -31.10% |
| Return on Capital (ROIC) | -32.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.24M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.94% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -11.94% |
| 50-Day Moving Average | 12.85 |
| 200-Day Moving Average | 11.09 |
| Relative Strength Index (RSI) | 51.73 |
| Average Volume (20 Days) | 312,364 |
Short Selling Information
The latest short interest is 1.14 million, so 2.31% of the outstanding shares have been sold short.
| Short Interest | 1.14M |
| Short Previous Month | 904,713 |
| Short % of Shares Out | 2.31% |
| Short % of Float | 4.93% |
| Short Ratio (days to cover) | 6.36 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -105.08M |
| Pretax Income | -90.80M |
| Net Income | -90.80M |
| EBITDA | -90.79M |
| EBIT | -90.80M |
| Earnings Per Share (EPS) | -$2.21 |
Balance Sheet
The company has $338.57 million in cash and no debt, giving a net cash position of $338.57 million or $6.82 per share.
| Cash & Cash Equivalents | 338.57M |
| Total Debt | n/a |
| Net Cash | 338.57M |
| Net Cash Per Share | $6.82 |
| Equity (Book Value) | 328.05M |
| Book Value Per Share | 6.61 |
| Working Capital | 327.62M |
Cash Flow
In the last 12 months, operating cash flow was -$87.54 million and capital expenditures -$59,000, giving a free cash flow of -$87.60 million.
| Operating Cash Flow | -87.54M |
| Capital Expenditures | -59,000 |
| Free Cash Flow | -87.60M |
| FCF Per Share | -$1.95 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MLYS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -81.31% |
| Shareholder Yield | -81.31% |
| Earnings Yield | -13.85% |
| FCF Yield | -13.37% |
Analyst Forecast
The average price target for MLYS is $30.00, which is 127.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.00 |
| Price Target Difference | 127.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 5.03% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |